MedTrace Logo

PREDICT Therapy Selection for JAK, T-cell, or IL-6 Inhibitor Therapies Using a Molecular Signature Response Classifier (PREDICT)

NCT06390709 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1100

Last updated 2024-04-30

No results posted yet for this study

Summary

Prospective, multi-center-observational study conducted within the US, collecting patient samples for research and development to train, test, and validate precision medicine classifiers. These molecular signature response classifiers (MSRC) aim to predict response status to JAK, T-cell, and IL-6 inhibitor therapies in patients with rheumatoid arthritis (RA).

Conditions

Interventions

OTHER

Lab Collection Only

2 Paxgene and 1 SST tubes will be collected at 2 timepoints throughout the study.

Sponsors & Collaborators

  • Scipher Medicine

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-08
Primary Completion
2025-06-30
Completion
2025-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06390709 on ClinicalTrials.gov